EGFR inhibitors: clinical results.
De Marinis
Filippo
F
Fifth Operative Unit of Pulmonary Oncology, Department of Respiratory Diseases, Carlo Forlanini Hospital, Rome, Italy.
Nelli
Fabrizio
F
D'Auria
Giuliana
G
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D002454:Cell Differentiation; D002455:Cell Division; D002470:Cell Survival; D002986:Clinical Trials as Topic; D004815:Epidermal Growth Factor / Q000037:antagonists & inhibitors; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D005260:Female; D000077156:Gefitinib; D015972:Gene Expression Regulation, Neoplastic; D006258:Head and Neck Neoplasms / Q000188:drug therapy; D006801:Humans; D008024:Ligands; D008175:Lung Neoplasms / Q000188:drug therapy; D010051:Ovarian Neoplasms; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011799:Quinazolines / Q000009:adverse effects / Q000494:pharmacology*; D013534:Survival
D000970:Antineoplastic Agents; D008024:Ligands; D011799:Quinazolines; D004815:Epidermal Growth Factor; D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases; D000077156:Gefitinib